Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer reports successful Nexavar phase III trial

Bayer reports successful Nexavar phase III trial

28th August 2007

Bayer HealthCare and Onyx Pharmaceuticals have this week reported a positive independent data monitoring committee review of its Asia-Pacific regional phase III clinical trial of Nexavar (sorafenib) as a treatment for patients with advanced hepatocellular carcinoma.

The committee found that administration with the compound resulted in significantly improved progression-free survival, time to progression and overall survival.

Following a recommendation from the independent committee, Bayer announced an early termination of the trial to enable all patients to gain access to the treatment.

Nexavar is an orally-administered treatment that targets tumour vasculature and tumour cells. In clinical trials it has been shown to affect cell proliferation and angiogenesis to inhibit cancer growth.

It is currently approved in a number of countries worldwide, European Union nations, as a treatment for advanced kidney cancer.

Dr Ann-Lii Cheng, principal investigator and professor of medicine at the National Taiwan University Hospital, said: “These study results confirm that Nexavar’s efficacy and tolerability in liver cancer extends across ethnic groups and geographies and suggest that Nexavar could meet a tremendous unmet need for patients and families impacted by this devastating disease.”

She added that the high rate of hepatitis B infections in the Asia Pacific region has resulted in a rise in the rate of liver cancer.

In June 2007, Bayer presented the results of a phase III clinical study of Nexavar at the annual conference of the American Society of Clinical Oncology, with patients receiving the compound exhibiting a 44 per cent increase in overall survival.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.